Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Enliven Therapeutics Inc shares valued at $276,025 were sold by Lyssikatos Joseph P on Oct 20 ’25. At $22.08 per share, Lyssikatos Joseph P sold 12,500 shares. The insider’s holdings dropped to 915,188 shares worth approximately $16.75 million following the completion of this transaction.
Also, Kintz Samuel sold 12,500 shares, netting a total of over 266,654 in proceeds. Following the sale of shares at $21.33 each, the insider now holds 902,892 shares.
Before that, Lyssikatos Joseph P had added 12,500 shares to its account. In a trade valued at $267,625, the Officer bought Enliven Therapeutics Inc shares for $21.41 each.
As published in their initiating research note from Goldman on June 16, 2025, Enliven Therapeutics Inc [ELVN] has been a Buy and the price target has been revised to $37. Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. As of September 09, 2024, H.C. Wainwright has initiated its “Buy” rating for ELVN. Earlier on June 11, 2024, Robert W. Baird initiated its rating. Their recommendation was “an Outperform” for ELVN stock.
Analyzing ELVN Stock Performance
On last trading session, Enliven Therapeutics Inc [NASDAQ: ELVN] plunged -1.08% to $18.3. The stock’s lowest price that day was $17.81, but it reached a high of $18.56 in the same session. During the last five days, there has been a drop of approximately -23.65%. Over the course of the year, Enliven Therapeutics Inc shares have dropped approximately -33.82%. Shares of the company reached a 52-week high of $25.37 on 01/03/25 and a 52-week low of $13.30 on 04/10/25.
Support And Resistance Levels for Enliven Therapeutics Inc (ELVN)
According to the 24-hour chart, there is a support level at 17.89, which, if violated, would cause prices to drop to 17.47. In the upper region, resistance lies at 18.64. The next price resistance is at 18.97. RSI (Relative Strength Index) is 38.04 on the 14-day chart, showing neutral technical sentiment.
Is Enliven Therapeutics Inc subject to short interest?
Stocks of Enliven Therapeutics Inc saw a sharp rise in short interest on 2025-10-15 jumping by 1.57 million shares to 6.42 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 4.86 million shares. A jump of 24.38% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 11.45 of the overall float, the days-to-cover ratio (short ratio) jumped to 11.45.
Which companies own the most shares of Enliven Therapeutics Inc (ELVN)?
In terms of Enliven Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 52 in the next 12 months, up nearly 181.08% from the previous closing price of $18.5. Analysts anticipate Enliven Therapeutics Inc stock to reach 52 by 2025, with the lowest price target being 52. In spite of this, 0 analysts ranked Enliven Therapeutics Inc stock as nan at the end of 2025. On April 09, 2024, Mizuho assigned a price target of “a Buy” to the stock and initiated coverage with a $34.
